The US FDA has approved a combination of avutometinib and defactinib for the treatment of adult patients with recurrent low-grade serous ovarian cancer harboring a mutation in the Kirsten rat sarcoma virus gene (KRAS). It is the first and only FDA-approved therapy for this disease. The approval was granted under the FDA’s accelerated approval program, based on clinical trial findings.
Clinical evidence In a clinical trial involving 57 adult patients, the combination therapy achieved a 44% overall response rate, with the duration of response ranging from 3.3 to 31.1 months. Dosage and administration Available as avutometinib capsules and defactinib tablets in a co-pack Avutometinib 3.2 mg: Orally twice weekly (Day 1 and Day 4) for the first three weeks of each four-week cycle Defactinib 200 mg: Orally twice daily for the first three weeks of each four-week cycle Contraindications None…
